The 2026 programme will spotlight CAR-T therapy (autoimmune conditions), rare disease gene therapy, cell therapy and strategies for commercialising innovations from lab to market. Alongside keynote talks and panel discussions, the symposium will feature talks and poster presentations by early career researchers, offering fresh perspectives on novel therapeutics and emerging technologies. Delegates will gain insights into UCL’s pioneering work, clinical applications, and strategic partnerships, while networking sessions throughout the day provide invaluable opportunities to connect with experts and foster collaborations across the therapeutic innovation ecosystem.
